Literature DB >> 9364983

Bleeding classification in clinical trials: observer variability and clinical relevance.

Y P Graafsma1, M H Prins, A W Lensing, R J de Haan, M V Huisman, H R Büller.   

Abstract

To evaluate the bleeding classification in a recent trial on venous thrombosis treatment, a selection of reported bleeding episodes was adjudicated twice by an independent committee and graded by the treating physician and independent clinical experts on the clinical severity and impact on the patient's life. The kappa values for the dichotomy major bleeding versus minor or no bleeding were 0.79 (95% CI, 0.57-1.0) for the agreement between the two members of the adjudication committee and 0.77 (95% CI, 0.52-1.0) for the agreement between both adjudication sessions. The kappa values for the dichotomy major or minor bleeding versus no bleeding were 0.42 and 0.44. The weighted kappa values for the agreement between the treating physician and the independent experts were 0.76 for the clinical severity and 0.79 for the impact on the patient's life (95% CI, 0.63-0.88 and 0.70-0.89). The association between the adjudication result expressed as major bleeding or minor or no bleeding and the clinical grading by the treating physician resulted in an ROC curve with an area under the curve of 0.98 for the clinical severity and 0.99 for the impact on the patient's life. The dichotomy major or minor bleeding versus no bleeding resulted in areas under the curve of 0.70 and 0.66. In conclusion, the applied criteria for major bleeding are reproducible and clinically relevant. The criteria for minor bleeding are not reproducible and are less associated with the observed clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364983

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.

Authors:  Pål O Borgen; Ola E Dahl; Olav Reikerås
Journal:  Clin Orthop Relat Res       Date:  2012-04-03       Impact factor: 4.176

Review 2.  Anticoagulation therapy for venous thromboembolism.

Authors:  David K Cundiff
Journal:  MedGenMed       Date:  2004-09-09

3.  Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Authors:  Scott Worley; Christine Short; Jeff Pike; David Anderson; Jo-Anne Douglas; Kara Thompson
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 4.  Safety of treatment with oral anticoagulants in the elderly. A systematic review.

Authors:  B A Hutten; A W Lensing; R A Kraaijenhagen; M H Prins
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

5.  Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients.

Authors:  Andreas Link; Matthias Klingele; Timo Speer; Ranja Rbah; Janine Pöss; Anne Lerner-Gräber; Danilo Fliser; Michael Böhm
Journal:  Crit Care       Date:  2012-05-29       Impact factor: 9.097

6.  Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study.

Authors:  Kenneth W Mahaffey; Robert A Harrington; Martijn Akkerhuis; Neal S Kleiman; Lisa G Berdan; Brian S Crenshaw; Barbara E Tardiff; Christopher B Granger; Ingrid DeJong; Manju Bhapkar; Petr Widimsky; Ramón Corbalon; Kerry L Lee; Jaap W Deckers; Maarten L Simoons; Eric J Topol; Robert M Califf
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001-07-17

7.  Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome.

Authors:  Chakradhar Venkata; Rahul Kashyap; J Christopher Farmer; Bekele Afessa
Journal:  J Intensive Care       Date:  2013-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.